PTI-2
From Infogalactic: the planetary knowledge core
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
N-(2-methoxyethyl)-N-((2-(1-pentyl-1H-indol-3-yl)thiazol-4-yl)methyl)propan-2-amine
|
|
| Clinical data | |
| Legal status |
|
| Identifiers | |
| CAS Number | 1400742-45-1 |
| Chemical data | |
| Formula | C23H33N3OS |
| Molecular mass | 399.60 g/mol |
|
|
|
|
PTI-2 is an indole-based synthetic cannabinoid.[1] It is one of few synthetic cannabinoids containing a thiazole group and is closely related to PTI-1. These compounds may be viewed as simplified analogues of indole-3-heterocycle compounds originally developed by Organon and subsequently further researched by Merck.[2][3][4][5]
See also
References
- ↑ Lua error in package.lua at line 80: module 'strict' not found.
- ↑ Julia Adam-Worrall, et al. (Indol-3-yl) heterocycle derivatives as agonists of the cannabinoid CB1 receptor. Patent US 7700634, priority date 5 March 2004
- ↑ Paul David Ratcliffe, et al. Indole Derivatives. Patent US 7763732, priority date 24 August 2005
- ↑ Julia Adam, et al. Indole Derivatives. Patent WO 2008/101995, priority date 22 February 2007
- ↑ Takao Kiyoi, et al. Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists. Bioorganic and Medicinal Chemistry Letters 2011; 21(6):1748-1753. doi: 10.1016/j.bmcl.2011.01.082
<templatestyles src="Asbox/styles.css"></templatestyles>
 |
This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |
Categories:
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Articles containing unverified chemical infoboxes
- Indoles
- Thiazoles
- Cannabinoids
- Designer drugs
- Cannabinoid stubs
